The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Canadian Journal of Cardiology

• Publication date

  2006-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0828-282X(06)70986-2PMID 16498512PMCID PMC2780832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug-eluting Stents

  2009cited by this paper
• First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study.

  2007cited by this paper
• p53 and apoptosis.

  2007cited by this paper
• A Randomized Double-blind Placebo-controlled Trial

  2004cited by this paper
• Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial

  2004cited by this paper
• The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).

  2004influential reference
• Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial

  2004cited by this paper
• The Retinoblastoma Protein and Cell Cycle Control Review

  2004cited by this paper
• Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery

  2004cited by this paper
• Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer

  2004cited by this paper
• Rapamycin Analogs for Stent-Based Local Drug Delivery

  2004influential reference
• First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial.

  2004influential reference
• 843-2 Everolimus-eluting stents for the prevention of restenosis: Results of the FUTURE II trial

  2004cited by this paper
• A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

  2004cited by this paper
• TOR of the cell cycle: Are there important implications for diabetics in the era of the drug‐eluting stent?

  2004cited by this paper
• Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.

  2004influential reference
• Advanced c‐myc antisense (AVI‐4126)‐eluting phosphorylcholine‐coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model

  2004cited by this paper
• ABT-578-Eluting Stents

  2004cited by this paper
• Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.

  2004cited by this paper
• Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties.

  2004influential reference
• Preclinical restenosis models and drug-eluting stents: still important, still much to learn.

  2004cited by this paper
• Local cyclin‐dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug‐ eluting stents to prevent neointima formation following vascular injury

  2004influential reference
• Everolimus for stent-based intracoronary applications.

  2004cited by this paper
• Drug-eluting stents.

  2004cited by this paper
• Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry

  2004cited by this paper
• Perspective in progress of cardiovascular gene therapy.

  2004cited by this paper
• Drug-eluting stents: the end of restenosis?

  2004cited by this paper
• Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions.

  2004cited by this paper
• Perlecan-Induced Suppression of Smooth Muscle Cell Proliferation Is Mediated Through Increased Activity of the Tumor Suppressor PTEN

  2004cited by this paper
• Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.

  2004cited by this paper
• Cell-cycle targeted therapies.

  2004cited by this paper
• Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).

  2003influential reference
• Specific Contribution of Estrogen Receptors on Mitogen-Activated Protein Kinase Pathways and Vascular Cell Activation

  2003cited by this paper
• Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

  2003influential reference
• Transcription Factor Decoys for the Prevention of Vein Bypass Graft Failure

  2003cited by this paper
• The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer

  2003cited by this paper
• Chimera analysis supports a predominant role of PDGFRbeta in promoting smooth-muscle cell chemotaxis after arterial injury.

  2003influential reference
• Pilot Trial of Oral Rapamycin for Recalcitrant Restenosis

  2003cited by this paper
• Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions

  2003cited by this paper
• Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits

  2003influential reference
• Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.

  2003cited by this paper
• Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial).

  2003cited by this paper
• Perspectives of Drug-Eluting Stents

  2002cited by this paper
• A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

  2002cited by this paper
• Inhibition of Vascular Smooth Muscle Cell Proliferation, Migration, and Survival by the Tumor Suppressor Protein PTEN

  2002influential reference
• Morphological Predictors of Restenosis After Coronary Stenting in Humans

  2002cited by this paper
• Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION

  2002influential reference
• Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial

  2002cited by this paper
• Estrogen‐eluting, phosphorylcholine‐coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model

  2002cited by this paper
• Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model.

  2002influential reference
• Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial.

  2002cited by this paper
• Host bone-marrow cells are a source of donor intimal smooth- muscle–like cells in murine aortic transplant arteriopathy

  2001cited by this paper
• Update on In-stent Restenosis.

  2001cited by this paper
• Gene Expression Profiling of Human Stent-Induced Neointima by cDNA Array Analysis of Microscopic Specimens Retrieved by Helix Cutter Atherectomy: Detection of FK506-Binding Protein 12 Upregulation

  2001influential reference
• Adenovirus-mediated Expression of a Truncated PDGFβ Receptor Inhibits Thrombosis and Neointima Formation in an Avian Arterial Injury Model

  2001influential reference
• Formulation and Delivery Mode Affect Disposition and Activity of Tyrphostin-Loaded Nanoparticles in the Rat Carotid Model

  2001cited by this paper
• Circulating Bone Marrow Cells Can Contribute to Neointimal Formation

  2001cited by this paper
• Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration.

  2001cited by this paper
• Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity

  2001cited by this paper
• Role for p 27 Kip 1 in Vascular Smooth Muscle Cell Migration

  2001cited by this paper
• Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial.

  2001cited by this paper
• Perlecan inhibits smooth muscle cell adhesion to fibronectin: Role of heparan sulfate

  2001cited by this paper
• The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound.

  2001cited by this paper
• Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery.

  2001cited by this paper
• Cell Cycle Protein Expression in Vascular Smooth Muscle Cells In Vitro and In Vivo Is Regulated Through Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin

  2001cited by this paper
• FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle

  2001cited by this paper
• Circulating smooth muscle progenitor cells contribute to atherosclerosis

  2001cited by this paper
• Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids).

  2001cited by this paper
• Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis.

  2000cited by this paper
• Expression of Interleukin-1β, Interleukin-1 Receptor, and Interleukin-1 Receptor Antagonist mRNA in Rat Carotid Artery after Balloon Angioplasty

  2000cited by this paper
• Local Drug Delivery During Percutaneous Coronary Intervention.

  2000cited by this paper
• Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis

  2000cited by this paper
• Direct Evidence for Cytokine Involvement in Neointimal Hyperplasia

  2000cited by this paper
• Expression of interleukin-1beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty.

  2000cited by this paper
• Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia.

  2000cited by this paper
• Histologic Evidence of Foreign Body Granulation Tissue and de novo Lesions in Patients with Coronary Stent Restenosis

  2000cited by this paper
• Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries

  2000cited by this paper
• Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats.

  2000cited by this paper
• Growth factors stimulate neointimal cells in vitro and increase the thickness of the neointima formed at the neck of porcine aneurysms treated by embolization.

  2000influential reference
• Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation.

  1999cited by this paper
• Perlecan Mediates the Antiproliferative Effect of Apolipoprotein E on Smooth Muscle Cells

  1999cited by this paper
• Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.

  1999cited by this paper
• Adenovirus-mediated delivery of the Gax transcription factor to rat carotid arteries inhibits smooth muscle proliferation and induces apoptosis

  1999cited by this paper
• Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model.

  1999cited by this paper
• Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.

  1999cited by this paper
• Adenovirus-Mediated Expression of a Ribozyme to c-mybmRNA Inhibits Smooth Muscle Cell Proliferation and Neointima Formation In Vivo

  1999cited by this paper
• Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells.

  1999cited by this paper
• Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation.

  1999cited by this paper
• Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.

  1999cited by this paper
• Protein phosphorylation and signal transduction.

  1999cited by this paper
• ATP-site directed inhibitors of cyclin-dependent kinases.

  1999cited by this paper
• Relationship between cell migration and cell cycle during the initiation of epithelial to fibroblastoid transition.

  1999cited by this paper
• Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat.

  1999cited by this paper
• A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.

  1999cited by this paper
• A randomized comparison of trapidil (triazolopyrimidine), a platelet‐derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz‐Schatz stent implantation

  1999cited by this paper
• Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation.

  1999cited by this paper
• Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.

  1999cited by this paper
• Pathobiologic responses to stenting.

  1998cited by this paper
• PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine.

  1998cited by this paper

• Identification of the Neointimal Hyperplasia-Related LncRNA-mRNA-Immune Cell Regulatory Network in a Rat Carotid Artery Balloon Injury Model.

  2024cites this paper
• Factors Influencing 1st and 2nd Generation Drug-Eluting Stent Performance: Understanding the Basic Pharmaceutical Drug-in-Polymer Formulation Factors Contributing to Stent Thrombosis Do We Really Need to Eliminate the Polymer?

  2021cites this paper
• Shared genetic architecture between neuroticism, coronary artery disease and cardiovascular risk factors

  2021cites this paper
• The biological relevance of pigment epithelium-derived factor on the path from aging to age-related disease.

  2021cites this paper
• Imperatorin reduces the inflammatory response of atherosclerosis by regulating MAPKs signaling pathway in vivo and in vitro.

  2020cites this paper
• Imperatorin alleviates the abnormal proliferation, migration, and foaming of ox-LDL-induced VSMCs through regulating PI3K/Akt/mTOR signaling pathway

  2020cites this paper
• Polymeric-Ceramic Nanocomposites Toxicity

  2020cites this paper
• Pathogenesis and Prevention of Vascular Access Failure

  2019cites this paper
• Polysaccharides from Poria cocos (PCP) inhibits ox-LDL-induced vascular smooth muscle cells proliferation and migration by suppressing TLR4/NF-κB p65 signaling pathway

  2019cites this paper
• INHIBITORY EFFECT OF COLCHICINE ON VASCULAR SMOOTH MUSCLE CELL PROLIFERATION INDUCED BY PLATELET-DERIVED GROWTH FACTOR-BB

  2018cites this paper
• EFFECT OF VASCULAR SMOOTH MUSCLE CELL PROLIFERATION OF URSOLIC ACID

  2018cites this paper
• Methyl Protodioscin, a Steroidal Saponin, Inhibits Neointima Formation in Vitro and in Vivo.

  2016cites this paper
• Alkaloid rich fraction from Nelumbo nucifera targets VSMC proliferation and migration to suppress restenosis in balloon-injured rat carotid artery.

  2016cites this paper
• Fibronectin/phosphorylcholine coatings on fluorocarboned surfaces : a study upon adsorption and grafting processes

  2016cites this paper
• GAX and HOXA5

  2016cites this paper
• HCdc14A is involved in cell cycle regulation of human brain vascular endothelial cells following injury induced by high glucose, free fatty acids and hypoxia.

  2015cites this paper
• The COP9 signalosome and vascular function: intriguing possibilities?

  2015cites this paper
• Salusin-&bgr; Induces Smooth Muscle Cell Proliferation by Regulating Cyclins D1 and E Expression Through MAPKs Signaling Pathways

  2015cites this paper
• What Is the Optimal Stent Design? – The Pathologist’s Opinion

  2015cites this paper
• Arterial territory-specific phosphorylated retinoblastoma protein species and CDK2 promote differences in the vascular smooth muscle cell response to mitogens

  2014cites this paper
• Pathophysiology of superficial femoral artery in-stent restenosis.

  2014cites this paper
• The effects of artemisinin on the proliferation and apoptosis of vascular smooth muscle cells of rats

  2014cites this paper
• Epigallocatechin-3-gallate inhibits proliferation of human aortic smooth muscle cells via up-regulating expression of mitofusin 2.

  2014cites this paper
• Biological responses in stented arteries.

  2013influential citation
• Cell cycle regulator geminin is dispensable for the proliferation of vascular smooth muscle cells

  2013cites this paper
• Pigment epithelium-derived factor reduces the PDGF-induced migration and proliferation of human aortic smooth muscle cells through PPARγ activation.

  2012influential citation
• Site Specific Controlled Release for Cardiovascular Disease: Translational Directions

  2012cites this paper
• Valsartan inhibits angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2

  2012cites this paper
• Valsartan inhibits angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2

  2012cites this paper
• Inhibitory effect of calcitonin gene-related peptide on hypoxia-induced rat pulmonary artery smooth muscle cells proliferation: role of ERK1/2 and p27.

  2012cites this paper
• Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R).

  2012cites this paper
• Einfluss der endothelialen DNA abhängigen Proteinkinase, DNA- PK, auf wachstumsfaktorabhängige angiogene Prozesse und Sig- naltransduktion

  2011cites this paper
• Comparison of restenosis rate with sirolimus-eluting stent i n STEMI patients with and without diabetes at 6-month angiographic follow-up

  2011cites this paper
• 2,3,4′,5‐Tetrahydroxystilbene‐2‐O‐β‐d‐glucoside inhibits platelet‐derived growth factor‐induced proliferation of vascular smooth muscle cells by regulating the cell cycle

  2011cites this paper
• Calcium-sensitive Mmechanisms in Vascular Smooth Muscle Cell Cycle Progression as Targets for Therapy

  2011cites this paper
• Multi-ligand nanoparticles for targeted drug delivery to the injured vascular wall

  2010cites this paper
• Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats

  2010cites this paper
• Bilirubin and Biliverdin Treatment of Atherosclerotic Diseases

  2007cites this paper
• Induction of necrosis and apoptosis to KB cancer cells by sanguinarine is associated with reactive oxygen species production and mitochondrial membrane depolarization.

  2007cites this paper